Ann Söderström
University of Gothenburg
11 Papers
269 Citations
Ann Söderström is an academic researcher from University of Gothenburg. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 10, co-authored 11 publications. Previous affiliations of Ann Söderström include Sahlgrenska University Hospital.
Chat about Author
Papers
Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission
TL;DR: Viremia was also relatively high in some HBeAg-negative mothers, and both viremia and ALT increased significantly late in pregnancy or shortly after delivery, and the value of measuring HBV DNA in the pregnant woman to modify immunoprophylaxis to her infant needs further study.
144
Phylogeny of African complete genomes reveals a West African genotype A subtype of hepatitis B virus and relatedness between Somali and Asian A1 sequences.
TL;DR: It was found that West African strains seem to constitute a new subgroup, A3, of non-European genotype A HBV, and it is proposed here that the A2 subtype originates from southern Africa and was imported to Europe around 500 years ago or later.
79
EHEC O157 outbreak in Sweden from locally produced lettuce, August-September 2005.
TL;DR: An outbreak of enterohaemorrhagic Escherichia coli O157 VT2 infections is known to have affected 120 people on the west coast of Sweden between 16 August and 10 September 2005.
66
Histologic activity of childhood chronic hepatitis B related to viremia levels, genotypes, mutations, and epidemiologic factors.
TL;DR: Severe HBeAg-negative hepatitis with high HBV DNA levels and mutations in the core promoter or precore regions seems to be less common in children than in adults, and C-1858 strains may be more pathogenic.
16
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
Magnus Lindh,Ingrid Uhnoo,Jonas Bläckberg,Ann-Sofi Duberg,Styrbjörn Friman,Björn Fischler,Olof Karlström,Gunnar Norkrans,Olle Reichard,Per Sangfeldt,Ann Söderström,Anders Sönnerborg,Ola Weiland,Rune Wejstål,Johan Wiström +14 more
TL;DR: In general, pegylated interferon alpha-2a is recommended as first-line treatment, in particular for HBeAg-positive patients with HBV genotypes A or B, and among nucleoside analogues, entecavir is the first choice and adefovir or tenofovir can be used as alternatives.
15